Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health

Announcer:
Welcome to NeuroFrontiers on ReachMD. On this episode, we’ll hear from Dr. Christopher Lock, who’s a Clinical Associate Professor of Neurology and the Clinical Trial Director of the Multiple Sclerosis and Neuroimmunology Program at Stanford University School of Medicine. He’ll discuss cognitive impairment in patients with multiple sclerosis. Here’s Dr. Lock now.
Dr. Lock:
To say a bit about cognitive impairment in patients with MS, the estimates vary, but it’s somewhere in the range of 30 to 60 or 70 percent. For most people it’s mild; for other people it’s more significant. The common things that people notice are processing speed, memory, and new learning, and sometimes other things like attention and executive function—things like planning, problem-solving, and organizing a task, like following a recipe. And it’s usually things that people notice gradually.
When we see people with cognitive symptoms, we like to inquire about other factors that might be playing into that, such as mood. So depression can affect one’s cognitive efficiency with fatigue and poor sleep. So addressing those is important. Not smoking, reducing alcohol intake, and keeping the brain active—learning helps to fire up the neurons and keep the myelin healthy—physical exercise, learning, and keeping the brain stimulated. There isn’t any set activity for that, but just something that people enjoy that keep the brain active.
Correcting vision loss and hearing loss in general seems to be protective for cognitive function, and then also, being on an effective disease-modifying therapy for MS. There’s long-term follow up data since the first drugs came out 30 years ago showing that getting on treatment and remaining on treatment is protective over the long term. It’s known that as well as myelin being injured, sometimes the axon can be injured in untreated MS, so we want to protect that, and the MS diagnostic criteria have tended towards earlier and earlier diagnosis, so getting onto treatment early and remaining on treatment is important. Disease-modifying therapies have been shown to reduce the risk of flare-ups, to reduce the risk of new lesions appearing on brain MRIs, and to protect the brain over time.
If somebody is experiencing cognitive symptoms, it’s quite helpful to have detailed neuropsychological testing that can help to define any areas where someone might be having difficulty, and we can request accommodation at work or at school. Also, cognitive rehabilitation can be very helpful. Depending on where you go—it can be a psychologist, speech therapist, or occupational therapist—they work on restorative approaches which are aimed at neuroplasticity. So ways of retaining information such as imagery, building associations, and repetition, as well as compensatory strategies, so having things all in one place and calendars and reminders. And then seeing a neurologist at regular intervals and doing MRI monitoring and just seeing how someone is doing clinically is important.
Announcer:
That was Dr. Christopher Lock talking about cognitive impairment in multiple sclerosis. To access this and other episodes in our series, visit NeuroFrontiers on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
The Future of MS Management: Novel Agents and Clinical Approaches
The Future of MS Management: Novel Agents and Clinical Approaches
NeuroFrontiersThe Future of MS Management: Novel Agents and Clinical Approaches
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
MS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
NeuroFrontiersMS Relapse vs Pseudo-Relapse After Infection: COVID-19 Shows Divergent Risk Pattern
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Recognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
NeuroFrontiersRecognizing MS: Understanding Symptoms and Avoiding Misdiagnosis
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
Epigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy
NeuroFrontiersEpigenetic Immune Signatures in Alzheimer’s: Implications for Diagnosis and Therapy